Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

A Comparison of Radiographic Joint Space Width Measurements Versus Ultrasonographic Assessment of Cartilage Thickness in Children with Juvenile Idiopathic Arthritis.

Pradsgaard DØ, Hørlyck A, Spannow AH, Heuck C, Herlin T.

J Rheumatol. 2019 Mar;46(3):301-308. doi: 10.3899/jrheum.170571. Epub 2018 Nov 15.

PMID:
30442828
2.

Genome Wide Mapping of Methylated and Hydroxyl-Methylated Cytosines Using a Modified HpaII Tiny Fragment Enrichment by Ligation Mediated PCR Tagged Sequencing Protocol.

Battachariyya S, Tytarenko R, Heuck C, Greally J, Verma A.

Methods Mol Biol. 2018;1792:167-177. doi: 10.1007/978-1-4939-7865-6_12.

PMID:
29797259
3.

Prednisolone Effects on Urine Cross-Linked N-Telopeptides of Type I Collagen (Ntx) Diurnal Rhythms in Children.

Wolthers OD, Heuck C.

Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):158-161. doi: 10.2174/1872213X12666180125101608.

PMID:
29366431
4.

Joint cartilage thickness and automated determination of bone age and bone health in juvenile idiopathic arthritis.

Twilt M, Pradsgaard D, Spannow AH, Horlyck A, Heuck C, Herlin T.

Pediatr Rheumatol Online J. 2017 Aug 10;15(1):63. doi: 10.1186/s12969-017-0194-9.

5.

The timing of administration of exogenous glucocorticoid affects 24hour growth hormone secretion in children.

Wolthers OD, Ramshanker N, Heuck C, Frystyk J.

Growth Horm IGF Res. 2017 Aug;35:40-44. doi: 10.1016/j.ghir.2017.06.004. Epub 2017 Jul 1.

PMID:
28688245
6.

Nasopharyngeal amyloidoma with osteolytic lesions leading to diagnosis of systemic light-chain amyloidosis.

Susanibar-Adaniya S, Mathur P, Henrich Lobo R, Alapat D, Kumar M, Heuck C, Thanendrarajan S.

Clin Case Rep. 2017 Apr 13;5(6):812-815. doi: 10.1002/ccr3.922. eCollection 2017 Jun.

7.

Multi-subgroup gene screening using semi-parametric hierarchical mixture models and the optimal discovery procedure: Application to a randomized clinical trial in multiple myeloma.

Matsui S, Noma H, Qu P, Sakai Y, Matsui K, Heuck C, Crowley J.

Biometrics. 2018 Mar;74(1):313-320. doi: 10.1111/biom.12716. Epub 2017 May 12.

PMID:
28498490
8.

Pubertal Progression and Reproductive Hormones in Healthy Girls With Transient Thelarche.

Lindhardt Johansen M, Hagen CP, Mieritz MG, Wolthers OD, Heuck C, Petersen JH, Juul A.

J Clin Endocrinol Metab. 2017 Mar 1;102(3):1001-1008. doi: 10.1210/jc.2016-2871.

PMID:
28009526
9.

The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma.

Pawlyn C, Kaiser MF, Heuck C, Melchor L, Wardell CP, Murison A, Chavan SS, Johnson DC, Begum DB, Dahir NM, Proszek PZ, Cairns DA, Boyle EM, Jones JR, Cook G, Drayson MT, Owen RG, Gregory WM, Jackson GH, Barlogie B, Davies FE, Walker BA, Morgan GJ.

Clin Cancer Res. 2016 Dec 1;22(23):5783-5794. Epub 2016 May 27.

10.

Assessment of Total Lesion Glycolysis by 18F FDG PET/CT Significantly Improves Prognostic Value of GEP and ISS in Myeloma.

McDonald JE, Kessler MM, Gardner MW, Buros AF, Ntambi JA, Waheed S, van Rhee F, Zangari M, Heuck CJ, Petty N, Schinke C, Thanendrarajan S, Mitchell A, Hoering A, Barlogie B, Morgan GJ, Davies FE.

Clin Cancer Res. 2017 Apr 15;23(8):1981-1987. doi: 10.1158/1078-0432.CCR-16-0235. Epub 2016 Oct 3.

11.

Dose-dense and less dose-intense total therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Sep 16;6:e471. doi: 10.1038/bcj.2016.85. No abstract available.

12.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ.

Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.

13.

Dose-dense and less dose-intense Total Therapy 5 for gene expression profiling-defined high-risk multiple myeloma.

Jethava Y, Mitchell A, Zangari M, Waheed S, Schinke C, Thanendrarajan S, Sawyer J, Alapat D, Tian E, Stein C, Khan R, Heuck CJ, Petty N, Avery D, Steward D, Smith R, Bailey C, Epstein J, Yaccoby S, Hoering A, Crowley J, Morgan G, Barlogie B, van Rhee F.

Blood Cancer J. 2016 Jul 29;6(7):e453. doi: 10.1038/bcj.2016.64. Erratum in: Blood Cancer J. 2016 Sep 16;6:e471.

14.

An inter-laboratory comparison of gaseous and liquid fumigation based methods for measuring microbial phosphorus (Pmic) in forest soils with differing P stocks.

Bergkemper F, Bünemann EK, Hauenstein S, Heuck C, Kandeler E, Krüger J, Marhan S, Mészáros É, Nassal D, Nassal P, Oelmann Y, Pistocchi C, Schloter M, Spohn M, Talkner U, Zederer DP, Schulz S.

J Microbiol Methods. 2016 Sep;128:66-68. doi: 10.1016/j.mimet.2016.07.006. Epub 2016 Jul 12.

PMID:
27422116
15.

Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?

Thanendrarajan S, Davies FE, Morgan GJ, Schinke C, Mathur P, Heuck CJ, Zangari M, Epstein J, Yaccoby S, Weinhold N, Barlogie B, van Rhee F.

Immunotherapy. 2016;8(3):367-84. doi: 10.2217/imt.15.118. Epub 2016 Feb 17. Review.

PMID:
26888183
16.

Phosphorus resorption by young beech trees and soil phosphatase activity as dependent on phosphorus availability.

Hofmann K, Heuck C, Spohn M.

Oecologia. 2016 Jun;181(2):369-79. doi: 10.1007/s00442-016-3581-x. Epub 2016 Feb 13.

PMID:
26875186
17.

A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.

Erickson SW, Stephens OW, Chavan SS, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Br J Haematol. 2016 Sep;174(6):991-3. doi: 10.1111/bjh.13830. Epub 2015 Nov 16. No abstract available.

PMID:
26568154
18.

Clinical value of molecular subtyping multiple myeloma using gene expression profiling.

Weinhold N, Heuck CJ, Rosenthal A, Thanendrarajan S, Stein CK, Van Rhee F, Zangari M, Hoering A, Tian E, Davies FE, Barlogie B, Morgan GJ.

Leukemia. 2016 Feb;30(2):423-30. doi: 10.1038/leu.2015.309. Epub 2015 Nov 3.

19.

Enhancing cancer clonality analysis with integrative genomics.

Peterson EA, Bauer MA, Chavan SS, Ashby C, Weinhold N, Heuck CJ, Morgan GJ, Johann DJ.

BMC Bioinformatics. 2015;16 Suppl 13:S7. doi: 10.1186/1471-2105-16-S13-S7. Epub 2015 Sep 25.

20.

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Erickson SW, Stephens OW, Chavan SS, Tian E, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Leukemia. 2015 Dec;29(12):2418-21. doi: 10.1038/leu.2015.238. Epub 2015 Aug 26. No abstract available.

21.

Inhibiting MEK in MAPK pathway-activated myeloma.

Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G.

Leukemia. 2016 Apr;30(4):976-80. doi: 10.1038/leu.2015.208. Epub 2015 Jul 31. No abstract available.

22.

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120).

Khan R, Dhodapkar M, Rosenthal A, Heuck C, Papanikolaou X, Qu P, van Rhee F, Zangari M, Jethava Y, Epstein J, Yaccoby S, Hoering A, Crowley J, Petty N, Bailey C, Morgan G, Barlogie B.

Haematologica. 2015 Sep;100(9):1214-21. doi: 10.3324/haematol.2015.124651. Epub 2015 May 28.

23.

Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma.

Sawyer JR, Tian E, Heuck CJ, Johann DJ, Epstein J, Swanson CM, Lukacs JL, Binz RL, Johnson M, Sammartino G, Zangari M, Davies FE, van Rhee F, Morgan GJ, Barlogie B.

Blood. 2015 Jun 11;125(24):3756-9. doi: 10.1182/blood-2015-03-632075. Epub 2015 May 5.

24.

The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma.

Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B.

Leukemia. 2015 Aug;29(8):1713-20. doi: 10.1038/leu.2015.65. Epub 2015 Mar 10.

25.

Cartilage thickness of the knee joint in juvenile idiopathic arthritis: comparative assessment by ultrasonography and magnetic resonance imaging.

Pradsgaard DØ, Fiirgaard B, Spannow AH, Heuck C, Herlin T.

J Rheumatol. 2015 Mar;42(3):534-40. doi: 10.3899/jrheum.140162. Epub 2014 Dec 15.

PMID:
25512475
26.

Leveraging the new with the old: providing a framework for the integration of historic microarray studies with next generation sequencing.

Bauer MA, Chavan SS, Peterson EA, Heuck CJ, Johann DJ.

BMC Bioinformatics. 2014;15 Suppl 11:S3. doi: 10.1186/1471-2105-15-S11-S3. Epub 2014 Oct 21.

27.

Revealing the inherent heterogeneity of human malignancies by variant consensus strategies coupled with cancer clonal analysis.

Peterson EA, Chavan SS, Bauer MA, Heuck CJ, Johann DJ.

BMC Bioinformatics. 2014;15 Suppl 11:S9. doi: 10.1186/1471-2105-15-S11-S9. Epub 2014 Oct 21.

28.

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma.

Erickson SW, Raj VR, Stephens OW, Dhakal I, Chavan SS, Sanathkumar N, Coleman EA, Lee JY, Goodwin JA, Apewokin S, Zhou D, Epstein J, Heuck CJ, Vangsted AJ.

Blood. 2014 Sep 18;124(12):2001-3. doi: 10.1182/blood-2014-07-586701. No abstract available.

29.

Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma.

Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J, Barlogie B.

Leukemia. 2014 Dec;28(12):2410-3. doi: 10.1038/leu.2014.232. Epub 2014 Jul 31. No abstract available.

30.

Artesunate overcomes drug resistance in multiple myeloma by inducing mitochondrial stress and non-caspase apoptosis.

Papanikolaou X, Johnson S, Garg T, Tian E, Tytarenko R, Zhang Q, Stein C, Barlogie B, Epstein J, Heuck C.

Oncotarget. 2014 Jun 30;5(12):4118-28.

31.

Translating a gene expression signature for multiple myeloma prognosis into a robust high-throughput assay for clinical use.

van Laar R, Flinchum R, Brown N, Ramsey J, Riccitelli S, Heuck C, Barlogie B, Shaughnessy JD Jr.

BMC Med Genomics. 2014 May 17;7:25. doi: 10.1186/1755-8794-7-25.

32.

In multiple myeloma, 14q32 translocations are nonrandom chromosomal fusions driving high expression levels of the respective partner genes.

Tian E, Sawyer JR, Heuck CJ, Zhang Q, van Rhee F, Barlogie B, Epstein J.

Genes Chromosomes Cancer. 2014 Jul;53(7):549-57. doi: 10.1002/gcc.22165. Epub 2014 Mar 17.

33.

Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease.

Sawyer JR, Tian E, Heuck CJ, Epstein J, Johann DJ, Swanson CM, Lukacs JL, Johnson M, Binz R, Boast A, Sammartino G, Usmani S, Zangari M, Waheed S, van Rhee F, Barlogie B.

Blood. 2014 Apr 17;123(16):2504-12. doi: 10.1182/blood-2013-12-546077. Epub 2014 Feb 4.

34.

Serial exome analysis of disease progression in premalignant gammopathies.

Zhao S, Choi M, Heuck C, Mane S, Barlogie B, Lifton RP, Dhodapkar MV.

Leukemia. 2014 Jul;28(7):1548-52. doi: 10.1038/leu.2014.59. Epub 2014 Feb 5. No abstract available.

35.

Patterns of central nervous system involvement in relapsed and refractory multiple myeloma.

Abdallah AO, Atrash S, Shahid Z, Jameel M, Grazziutti M, Apewokin S, Kumar NS, Restrepo A, Waheed S, Van Rhee F, Heuck CJ, Johann D Jr, Barlogie B, Usmani SZ.

Clin Lymphoma Myeloma Leuk. 2014 Jun;14(3):211-4. doi: 10.1016/j.clml.2013.11.004. Epub 2013 Nov 16.

PMID:
24373936
36.

Towards the integration, annotation and association of historical microarray experiments with RNA-seq.

Chavan SS, Bauer MA, Peterson EA, Heuck CJ, Johann DJ Jr.

BMC Bioinformatics. 2013;14 Suppl 14:S4. doi: 10.1186/1471-2105-14-S14-S4. Epub 2013 Oct 9.

37.

Reply to "Metronomic chemotherapy beyond misconceptions"--Haematologica 2013;98(11):e145.

Papanikolaou X, Heuck CJ, Barlogie B.

Haematologica. 2013 Nov;98(11):e149-50. doi: 10.3324/haematol.2013.098939. No abstract available.

38.

The 2014 Danish references from birth to 20 years for height, weight and body mass index.

Tinggaard J, Aksglaede L, Sørensen K, Mouritsen A, Wohlfahrt-Veje C, Hagen CP, Mieritz MG, Jørgensen N, Wolthers OD, Heuck C, Petersen JH, Main KM, Juul A.

Acta Paediatr. 2014 Feb;103(2):214-24. doi: 10.1111/apa.12468. Epub 2013 Dec 3. Erratum in: Acta Paediatr. 2016 Apr;105(4):434.

39.

Characterization of the molecular mechanism of the bone-anabolic activity of carfilzomib in multiple myeloma.

Hu B, Chen Y, Usmani SZ, Ye S, Qiang W, Papanikolaou X, Heuck CJ, Yaccoby S, Williams BO, Van Rhee F, Barlogie B, Epstein J, Qiang YW.

PLoS One. 2013 Sep 16;8(9):e74191. doi: 10.1371/journal.pone.0074191. eCollection 2013.

40.

Ten-year review of Danish children with chronic non-bacterial osteitis.

Ziobrowska-Bech A, Fiirgaard B, Heuck C, Ramsgaard Hansen O, Herlin T.

Clin Exp Rheumatol. 2013 Nov-Dec;31(6):974-9. Epub 2013 Aug 26.

PMID:
23981294
41.

Hematopoietic progenitor cell collection after autologous transplant for multiple myeloma: low platelet count predicts for poor collection and sole use of resulting graft enhances risk of myelodysplasia.

Papanikolaou X, Rosenbaum ER, Tyler LN, Sawyer J, Heuck CJ, Barlogie B, Cottler-Fox M.

Leukemia. 2014 Apr;28(4):888-93. doi: 10.1038/leu.2013.214. Epub 2013 Jul 15.

42.

Decreased cartilage thickness in juvenile idiopathic arthritis assessed by ultrasonography.

Pradsgaard DØ, Spannow AH, Heuck C, Herlin T.

J Rheumatol. 2013 Sep;40(9):1596-603. doi: 10.3899/jrheum.121077. Epub 2013 Jul 1.

PMID:
23818714
43.

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma.

Papanikolaou X, Szymonifka J, Rosenthal A, Heuck CJ, Mitchell A, Johann D Jr, Keller J, Waheed S, Usmani SZ, Van Rhee F, Bailey C, Petty N, Hoering A, Crowley J, Barlogie B.

Haematologica. 2013 Jul;98(7):1147-53. doi: 10.3324/haematol.2013.085183. Epub 2013 May 28.

44.

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.

Usmani SZ, Sawyer J, Rosenthal A, Cottler-Fox M, Epstein J, Yaccoby S, Sexton R, Hoering A, Singh Z, Heuck CJ, Waheed S, Chauhan N, Johann D, Abdallah AO, Muzaffar J, Petty N, Bailey C, Crowley J, van Rhee F, Barlogie B.

Blood. 2013 Jun 6;121(23):4753-7. doi: 10.1182/blood-2012-11-466961. Epub 2013 Apr 19.

45.

Myeloma is characterized by stage-specific alterations in DNA methylation that occur early during myelomagenesis.

Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB.

J Immunol. 2013 Mar 15;190(6):2966-75. doi: 10.4049/jimmunol.1202493. Epub 2013 Feb 13.

46.

Prednisolone reduces the ability of serum to activate the IGF1 receptor in vitro without affecting circulating total or free IGF1.

Frystyk J, Schou AJ, Heuck C, Vorum H, Lyngholm M, Flyvbjerg A, Wolthers OD.

Eur J Endocrinol. 2012 Dec 10;168(1):1-8. doi: 10.1530/EJE-12-0518. Print 2013 Jan.

PMID:
23038624
47.

Thalidomide in total therapy 2 overcomes inferior prognosis of myeloma with low expression of the glucocorticoid receptor gene NR3C1.

Heuck CJ, Szymonifka J, Hansen E, Shaughnessy JD Jr, Usmani SZ, van Rhee F, Anaissie E, Nair B, Waheed S, Alsayed Y, Petty N, Bailey C, Epstein J, Hoering A, Crowley J, Barlogie B.

Clin Cancer Res. 2012 Oct 1;18(19):5499-506. doi: 10.1158/1078-0432.CCR-12-0019. Epub 2012 Aug 1. Erratum in: Clin Cancer Res. 2013 Feb 1;19(3):752.

48.

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.

Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A.

Blood. 2012 Sep 6;120(10):2076-86. doi: 10.1182/blood-2011-12-399683. Epub 2012 Jul 2.

49.

Proteasome inhibitors and bone disease.

Qiang YW, Heuck CJ, Shaughnessy JD Jr, Barlogie B, Epstein J.

Semin Hematol. 2012 Jul;49(3):243-8. doi: 10.1053/j.seminhematol.2012.04.011. Review.

50.

Proteasome inhibitors: introduction.

Heuck CJ, Shaughnessy JD Jr.

Semin Hematol. 2012 Jul;49(3):193-5. doi: 10.1053/j.seminhematol.2012.05.001. No abstract available.

PMID:
22726541

Supplemental Content

Support Center